

Appl. No 10/561,162
Reply to Office Action of December 31, 2008

RECEIVED
CENTRAL FAX CENTER
JUN 01 2009

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Withdrawn) A method for preventing or attenuating atrial fibrillation (AF) promotion by atrial tachycardia in a subject comprising the administration of a therapeutically effective amount of a HMG-CoA reductase inhibitor.
2. (Withdrawn) A method as defined in claim 1, wherein said HMG-CoA reductase inhibitor is effective against longer-term atrial tachycardia remodeling.
3. (Withdrawn) A method as defined in claim 2, wherein said longer-term is greater than 24 hours.
4. (Withdrawn) A method as defined in claim 2, wherein said HMG-CoA reductase inhibitor is selected from the group consisting of: atorvastatin (Lipitor®), cerivastatin (Baycol®), fluvastatin (Lescol®), lovastatin (Mevacor®), Altacor®, pravastatin (Pravachol®), simvastatin (Zocor®), epistatin, eptastatin, mevinolin, and synvinolin.
5. (Withdrawn) A method as defined in claim 4, wherein said HMG-CoA

Appl. No 10/561,162

Reply to Office Action of December 31, 2008

reductase inhibitor is simvastatin (Zocor®).

6. (Withdrawn) A method as defined in claim 4, wherein said HMG-CoA reductase inhibitor is administered in an amount of about 0.1-2 mg/day.

7. (Withdrawn) A method as defined in claim 6, wherein said subject is a mammal.

8. (Withdrawn) A method as defined in claim 7, wherein said mammal is human.

9. (Currently amended) A method of reducing the incidence of a first occurrence of atrial fibrillation (AF) by substrate modification comprising the step of administering to a mammal in need thereof an amount of a statin drug therapeutically effective for reducing the incidence of a first occurrence of atrial fibrillation in the mammal.

10. (Canceled)

11. (Currently amended) A method as defined in claim 9~~claim 10~~, wherein said statin drug is simvastatin (Zocor®).

12. (Previously presented) A method as defined in claim 11, wherein said statin drug is administered in an amount of about 0.1-2 mg/day.

13. (Cancelled)

14. (Previously presented) A method as defined in claim 9, wherein said mammal is human.

Appl. No 10/561,162

Reply to Office Action of December 31, 2008

15. (Withdrawn) A method of attenuating atrial tachypacing (ATP) effects on effective refractory period (ERP) in right atrium (RA) appendage, posterior wall and inferior wall comprising the step of administering to a subject in need thereof a therapeutically effective amount of a statin drug.

16. (Withdrawn) A method as defined in claim 15, wherein said statin drug is chosen from the group consisting of: atorvastatin (Lipitor®), cerivastatin (Baycol®), fluvastatin (Lescol®), lovastatin (Mevacor®, Altocor®), pravastatin (Pravachol®), simvastatin (Zocor®), epistatin, eptastatin, mevinolin, and synvinolin.

17. (Withdrawn) A method as defined in claim 16, wherein said statin drug is simvastatin (Zocor®).

18. (Withdrawn) A method as defined in claim 16, wherein said statin drug is administered in an amount of about 0.1-2 mg/day.

19. (Withdrawn) A method as defined in claim 18, wherein said subject is a mammal.

20. (Withdrawn) A method as defined in claim 19, wherein said mammal is human.

21. (Withdrawn) A method for modulating atrial tachycardia-induced effects on CaV1.2 protein expression, said method comprising the step of administering to a subject an effective amount of a statin drug.

22. (Withdrawn) A method as defined in claim 21, wherein said statin drug